Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

39.75 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Legend Biotech Corp ADR

< Previous 1 2 3 4 5 6 Next >
LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its... 
Via Benzinga
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your... 
Via Benzinga
Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal. 
Via Talk Markets
The Latest Analyst Ratings For Legend Biotech
Via Benzinga
Assessing Legend Biotech: Insights From 15 Financial Analysts
Via Benzinga
Unveiling 18 Analyst Insights On Legend Biotech
Via Benzinga
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
9 Analysts Have This To Say About Legend Biotech
Via Benzinga
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by... 
Via Benzinga
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma. 
Via Investor's Business Daily
Where Legend Biotech Stands With Analysts
Via Benzinga
Peering Into Legend Biotech's Recent Short Interest
Via Benzinga
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
Via Benzinga
Looking Into Legend Biotech's Recent Short Interest
Via Benzinga
Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
Via Benzinga
Analyst Ratings For Legend Biotech
Via Benzinga
Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of... 
Via Benzinga
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product. 
Via Benzinga
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
Unveiling 9 Analyst Insights On Legend Biotech
Via Benzinga
Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
In the last three months, IBRX outperformed NVDA by over 3x. 
Via Talk Markets
LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024
LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
Exposures Product Safety
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration... 
Via Benzinga
Exposures Product Safety
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual... 
Via Benzinga
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... 
Via Benzinga
Exposures Product Safety
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.